Author

C. Sawyers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cell type annotation· 4 Organism:mouse· 4 Organism:human· 3 Assay:scRNA-seq· 3 Research Focus:clustering· 2 Research Focus:differential expression· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Gopalan· 3 shared R. Chaligne· 3 shared S. Zaidi· 3 shared D. Pe'er· 2 shared E. De Stanchina· 2 shared H. Zhao· 2 shared I. Masilionis· 2 shared J. Choi· 2 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Gopalan

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1

R. Romero, T. Chu, T. J. Gonzalez-Robles, P. Smith, Y. Xie, H. Kaur, S. Yoder, H. Zhao, C. Mao, W. Kang, M. Pulina, K. E. Lawrence, A. Gopalan, S. Zaidi, K. Yoo, , C. Sawyers

This study identifies ASCL1 as a critical driver of neuroendocrine lineage transition in prostate cancer using an in vivo model and spatial transcriptomics.

bioRxiv · Apr 9, 2024Cancer Biology

Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies

S. Zaidi, J. Park, J. M. Chan, M. Roudier, J. L. Zhao, A. Gopalan, K. M. Wadosky, R. A. Patel, E. Sayar, W. R. Karthaus, D. H. Kates, O. Chaudhary, T. Xu, I. Masilionis, L. Mazutis, , C. Sawyers

The paper uses single-cell analysis to study how cell surface antigen expression changes in treatment-resistant prostate cancer, revealing transcriptional heterogeneity and shared gene regulatory networks between NEPC and SCLC.

bioRxiv · Apr 9, 2024 · PreprintCancer Biology

Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer

E. Lee, Z. Zhang, C.-C. Chen, D. Choi, A. C. A. Rivera, E. Linton, Y.-j. Ho, J. Love, J. LaClair, J. Wongvipat, C. Sawyers

This study shows that treatment timing affects the path to androgen receptor signaling inhibitor resistance in prostate cancer, with resistance arising through different mechanisms depending on the tumor context.

bioRxiv · Mar 18, 2024 · PreprintCancer Biology

ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity

W. Feng, E. Ladewig, N. Salsabeel, H. Zhao, Y. S. Lee, A. Gopalan, M. Lange, H. Luo, W. Kang, N. Fan, E. Rosiek, E. De Stanchina, Y. Chen, B. S. Carver, C. S. Leslie, C. Sawyers

The paper identifies a stem-like proliferative state in prostate epithelial cells driven by ERG activation, which transitions to luminal cells and is associated with specific chromatin states.

bioRxiv · May 15, 2023Cancer Biology

Allosteric interactions prime androgen receptor dimerization and activation

E. Wasmuth, A. Vanden Broeck, J. R. LaClair, E. A. Hoover, K. E. Lawrence, N. Paknejad, K. J. Pappas, D. Matthies, B. Wang, W. Feng, P. A. Watson, J. C. Zinder, W. Karthaus, M. J. de la Cruz, R. K. Hite, , C. Sawyers

This study identifies allosteric interactions that prime androgen receptor dimerization and activation, revealing structural and functional mechanisms relevant to development and disease.

bioRxiv · Feb 20, 2022Biochemistry

Reversal of lineage plasticity in RB1/TP53-deleted prostate cancer through FGFR and Janus kinase inhibition

W. Karthaus, J. Chan, M. Setty, J. Love, S. Zaidi, Z.-N. Choo, S. Persad, J. LaClair, K. Lawrence, O. Chaudhary, T. Xu, I. Masilionis, L. Mazutis, R. Chaligne, D. Pe'er, C. Sawyers

This study identifies a pharmacological strategy to reverse lineage plasticity in prostate cancer by inhibiting FGFR and Janus kinase pathways.

bioRxiv · Nov 1, 2021 · PreprintCancer Biology